New Stability-Indicating RP-HPLC Method for Determination of Diclofenac Potassium and Metaxalone from their Combined Dosage Form by Panda, Sagar Suman et al.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
New Stability-Indicating RP-HPLC Method for 
Determination of Diclofenac Potassium and 
Metaxalone from their Combined Dosage Form 
Sagar Suman PANDA *, Debasis PATANAIK, Bera V. V. RAVI KUMAR 
Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical 
Sciences, Khodasingi, 760010, Berhampur (Orissa), India. 
* Corresponding author. E-mail: sagarguddu2002@gmail.com (S. S. Panda) 
Sci Pharm. 2012; 80: 127–137        doi:10.3797/scipharm.1109-16 
Published:   December 5
th 2011      Received:   September 22
nd 2011 
Accepted:   December 5
th 2011 
This article is available from: http://dx.doi.org/10.3797/scipharm.1109-16 
© Panda et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
A simple, precise and accurate isocratic RP-HPLC stability-indicating assay 
method has been developed to determine diclofenac potassium and 
metaxalone in their combined dosage forms. Isocratic separation was achieved 
on a Hibar-C18, Lichrosphere-100
® (250 mm × 4.6 mm i.d., particle size 5 µm) 
column at room temperature in isocratic mode, the mobile phase consists of 
methanol: water (80:20, v/v) at a flow rate of 1.0 ml/min, the injection volume 
was 20 μl and UV detection was carried out at 280nm.The drug was subjected 
to acid and alkali hydrolysis, oxidation, photolysis and heat as stress conditions. 
The method was validated for specificity, linearity, precision, accuracy, 
robustness and system suitability. The method was linear in the drug 
concentration range of 2.5–30 μg/ml and 20–240 μg/ml for diclofenac potassium 
and metaxalone, respectively. The precision (RSD) of six samples was 0.83 and 
0.93% for repeatability, and the intermediate precision (RSD) among six-sample 
preparation was 1.63 and 0.49% for diclofenac potassium and metaxalone, 
respectively. The mean recoveries were between 100.99–102.58% and 99.97–
100.01% for diclofenac potassium and metaxalone, respectively. The proposed 
method can be used successfully for routine analysis of the drug in bulk and 
combined pharmaceutical dosage forms. 
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Introduction 
Diclofenac Potassium (DIC),  potassium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate 
(Figure 1A),  is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-
inflammatory, analgesic, and antipyretic activities [1]. Metaxalone (MET), 5-[(3,5-dimethyl-
phenoxy)methyl]-1,3-oxazolidin-2-one (Figure 1B), is a skeletal muscle relaxant [2].  
Literature survey shows that no stability-indicating RP-HPLC method has been reported so 
far for the simultaneous estimation of both the drugs using mobile phase of methanol: 
water  (80:20%,  v/v).  Some of the reported methods for DIC  include UV-spectroscopic 
methods [3–6], RP-HPLC methods [7–10] and LC-MS method [11]. For MET the reported 
methods are UV-Spectroscopic method  [12], RP-HPLC method  [13, 14]  and LC-MS 
method  [15].  Only one RP-HPLC method  has been reported so far for simultaneous 
estimation of both the drugs  [16],  but the reported method is not stability-indicating in 
nature. The objective of this work was to develop a novel, simple, precise and rapid 
RP-HPLC method which can be used as a stability-indicating assay for combination drug 
product of DIC and MET.  
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Fig. 1.   Chemical structures of (A) Diclofenac potassium and (B)Metaxalone 
To establish the stability-indicating nature of the method, forced degradation  of drug 
substances and drug product was performed under stress conditions (acid, alkali, 
oxidation, thermal and photolysis), and stressed samples were analyzed by the proposed 
method. The method was also validated according to ICH guideline requirements [17]. 
Experimental 
Chemicals and Reagents 
Analytical Grade DIC and MET (purity > 99.5%) were procured from Sun Pharmaceuticals 
Industries Ltd., India. Methanol (Merck Ltd., Mumbai, India) was of HPLC grade. Analytical 
grade sodium hydroxide, hydrochloric acid and hydrogen peroxide were procured from 
S.D. Fine Chem. Ltd., Mumbai, India. The water for HPLC was obtained by using TKA 
Water Purification System, Germany. The combined tablet formulation (Flexura-D,  Sun 
Pharmaceuticals Industries Ltd., India) containing 50 mg of DIC and 400mg of MET was 
purchased from the local market. 
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HPLC Instrumentation and chromatographic conditions 
Quantitative HPLC was performed on a binary gradient HPLC with Shimadzu LC-10AT 
and LC-10AT VP Series HPLC pumps, with a 20 μl sample injection loop (manual) and 
SPD 10A VP series UV Visible detector. The output signal was monitored and integrated 
using Shimadzu Class-VP Version 6.12 SP1 Software. A Hibar-C18, Lichrosphere-100
® 
(250 mm × 4.6 mm i.d., particle size 5 µm) was used for separation. Chromatographic 
analysis was carried out at ambient temperature on the column using the methanol: water 
(80:20, v/v) as mobile phase at a flow rate of 1.0 ml/min in isocratic mode. The column 
back pressure was found to be 164 kgf/cm
2.The mobile phase utilizes no special prepa-
ration technique except filtration using 0.45µm filter paper. Afterward both the methanol 
and water were ultrasonicated (Enertech,India) up to 20 minutes for degassing prior to 
use. The UV detection wavelength was 280 nm. Water bath (Thermolab, India) and UV 
Chamber (Jain Scientific Glass Works, Ambala, India) were used for forced degradation 
study of the drugs. Analytical balance, Model-GR-202 (AND Instrument India Pvt. Ltd., 
Gurgaon, India) of sensitivity 0.1 mg was used to weigh the chemicals and reagents. 
Preparation of Standard and Sample Solution 
Standard stock solutions for both the drugs were prepared separately by dissolving 25 mg 
of the drugs in methanol up to 25 ml. The volumetric flasks having 10 ml of methanol were 
ultrasonicated for 5 minutes. Finally,  the volumes were made up to the mark with 
methanol, which gave 1000µg/ml solutions. From this a mixed standard stock solution was 
prepared so that the drugs DIC and MET were in the ratio equal to that of the marketed 
formulation (1:8) available. Working standard solutions of DIC and MET were prepared in 
the concentration ratio of 1:8.  
Twenty tablets were weighed accurately and finely powdered. A quantity of tablet powder 
equivalent to 25 mg of DIC and 200 mg of MET was accurately weighed and transferred 
into a 25 ml  volumetric flask, containing 10 ml  of mobile phase and ultrasonicated for 
20 min; the volume was made up to the mark and mixed well. The solution was filtered 
through a 0.2 μm filter to ensure the absence of particulate matter. The filtered solution 
was appropriately diluted with the mobile phase for analysis as already described. The 
amount of drug present in the sample solution was calculated by using the calibration 
curves. 
Method validation  
Specificity 
The specificity of the method was determined by checking the interference of any of the 
possible degradation products generated during the forced degradation study of the drugs. 
The forced degradation of the drug was carried out with 0.1 N HCl, 0.1 N NaOH, 3% v/v 
hydrogen peroxide, heat (80°C) and photolysis  (365 nm)  for determining the stability 
nature of the drugs. The degradation samples were prepared by taking suitable aliquots of 
the drug and drug product solutions, and then undertaking the respective stress testing 
procedures for each solution. After the fixed time period the treated test solutions were 
diluted up to the mark with mobile phase. For every stress condition three solutions were 
prepared as 10 µg/ml of DIC, 80 µg /ml  of MET and drug product solution containing 
10 µg/ml of DIC along with 80 µg/ml of MET. The specific stress conditions are described 
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Acidic degradation condition: 
Acidic degradation was carried out by adding 2 ml of 0.1N HCl, and after 45 minutes 
neutralizing the mixture by adding 0.1N NaOH. 
Alkali degradation condition. 
Alkali degradation was carried out by adding 2 ml of 0.1N NaOH, and after 45 
minutes neutralizing the mixture by adding 0.1N HCl. 
Oxidative degradation condition: 
Oxidative degradation was performed by exposing the drug to 2 ml of 3% (v/v) H2O2 
for 45 minutes. 
Thermal degradation condition: 
Thermal degradation was performed by heating the drug content at 80ºC on a 
thermostatically controlled water bath for 45 minutes. 
Photolytic degradation condition: 
Photolytic degradation was carried out by exposing the drug content to UV light 
(365nm) inside a UV chamber for 180 minutes. 
Linearity 
Eight point calibration curves were obtained in a concentration range from 2.5 to 30 µg/ml 
for  DIC  and 20 to 240 µg/ml  for  MET. Calibration curves were plotted by taking the 
average peak area (n=3) on y-axis and concentration (µg /ml) on x-axis for DIC and MET 
separately.  
Precision 
The repeatability (intra-day precision) of the method was ascertained from the peak areas 
obtained by actual determination of six replicates of a fixed amount of drug. For 
intermediate precision (inter-day precision) of the method the above same procedure was 
carried out by a different analyst on a different day under similar experimental conditions. 
The percent RSD values were calculated for each type of precision study. 
Accuracy 
To check the accuracy of the proposed method, recovery studies were carried out at 80, 
100 and 120% of the test concentration. The recovery study was performed three times at 
each level. The amount of DIC and MET present in the sample were calculated using the 
calibration curves.  
Robustness 
The robustness of the method was studied by very deliberately changing the composition 
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for 24 h. The method was also evaluated for different system suitability parameters like 
Retention time, Theoretical plate, Asymmetry and Resolution. 
Limit of detection and Limit of quantitation 
The limit of detection and limit of quantitation were separately determined based on the 
Signal to Noise ratio. For limit of detection the S/N ratio was taken as 3:1. For limit of 
quantitation the S/N ratio was taken as 10:1. 
Results and Discussion 
Optimization of the Chromatographic conditions  
Optimization of mobile phase was carried out based  on resolution, tailing factor and 
theoretical plates obtained for DIC and MET. During the trial runs both the drugs were 
tested with different mobile phase compositions like acetonitrile: water, acetonitrile: 0.01M 
tetra butyl ammonium hydrogen sulphate, methanol: water and methanol: 0.01M tetra butyl 
ammonium hydrogen sulphate at various compositions and flow rates. The mobile phase 
consisting of methanol: water (80:20, v/v) at a flow rate of 1.0 ml/min was selected which 
gave sharp, well-resolved peaks for DIC and MET. The retention times for DIC and MET 
were 1.808 and 3.758 minutes, respectively. The asymmetry for DIC and MET were 1.21 
and 1.13, respectively. UV spectra of DIC and MET in mobile phase ratio showed that both 
the drugs absorbed UV radiations appreciably at 280 nm, so the same was selected as the 
detection wavelength. The separation was carried out at room temperature.  Fig.  2 
represents the chromatograms of standard drugs, drugs in combined tablet formulation 
and blank mobile phase run, respectively. 
 
Fig. 2.   Chromatograms of (A) standard drugs, (B) drugs in combined dosage form, (C) 
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Specificity  
Specificity of the method was ascertained by checking any interference due to excipients 
or degradation products. No extra peaks were obtained either from the excipients used in 
the drug product or from the stress conditions applied on the drugs and drug product. 
Hence, there was no interference with the drug peaks. In acidic (45.12%), alkali (24.68%) 
and oxidation (16.97%) conditions DIC shows some significant degradation than compared 
to thermal (4.01%) and photolytic (3.48%) stress conditions. But the drug MET was found 
to be relatively more stable with very less degradation (1.05–4.39%) in all the applied 
stress conditions than compared to DIC. Fig. 3 represents the chromatograms of untreated 
drugs;  oxidation degraded drugs and thermally degraded drugs with drug products, 
respectively.  
Linearity 
The two eight point calibration curves were found to be linear over a concentration range 
of 2.5–30 µg/ml and 20–240 µg/ml for DIC and MET, respectively. The linear regression 
equations were y = 31587 x − 1914.6 and y = 4656.5 x + 6788.5 with correlation 
coefficients 0.9992 and 0.9994 for DIC and MET, respectively.  
 
Fig. 3.   A: Chromatograms of untreated drugs 
Each chromatogram represents (i) DIC (10 µg/ml), (ii) MET (80 µg/ml), (iii) 
combined dosage form with DIC (10 µg/ml) and MET (80 µg/ml) 
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Fig. 3.  B: Chromatograms of oxidation degraded drugs
 
Each chromatogram represents (i) DIC (10 µg/ml), (ii) MET (80 µg/ml), (iii) 
combined dosage form with DIC (10 µg/ml) and MET (80 µg/ml) 
 
Fig. 3.   C: Chromatograms of thermally degraded drugs
 
Each chromatogram represents (i) DIC (10 µg/ml), (ii) MET (80 µg/ml), (iii) 
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Precision 
The method was found to be precise as the % RSD values for repeatability and 
intermediate precision studies were well below 2%, confirming that the method was 
precise. The results are shown in Table 1. 
Tab. 1.   Precision of the method 
  Concentration 
(μg/ml) 
Peak Area
a 
±Standard Deviation 
% RSD 
Precision Type  DIC  MET  DIC  MET  DIC  MET 
Repeatability 
(Intraday, n=6)  10  80  305213.16 ± 
2533.09 
374156.16 ± 
3496.85  0.83  0.93 
Intermediate 
precision 
(Interday, n=6) 
10  80  303097.05 ± 
4959.05 
375515 ± 
1836.54  1.63  0.49 
a Mean of six determinations. 
 
Accuracy 
Accuracy of the method was determined by recoveries of DIC  and  MET  by standard 
addition methods. The average recoveries were 100.99–102.58% for DIC  and  
99.97–100.01% for MET, respectively. The values show high levels of accuracy of the 
method. The result of accuracy study is shown in Table 2. 
Tab. 2.   Accuracy of the method 
Recovery 
Type 
(%) 
Amount added 
(μg/ml) 
% Recovery
a ± 
Standard Deviation 
% RSD 
DIC  MET  DIC  MET  DIC  MET 
80  8  64  100.99 ± 0.99  100.01 ± 0.18  0.98  0.18 
100  10  80  101.46 ± 0.32  100.01 ± 0.33  0.32  0.33 
120  12  96  102.58 ± 0.28    99.97 ± 0.03  0.27  0.03 
a Mean of three determinations. 
 
Robustness 
Robustness of the method was ascertained by deliberately changing the mobile phase 
composition to methanol: water (79:21, v/v) by increasing percentage of water, the 
retention time for DIC  and  MET  were observed to be 1.850 and 3.767 minutes, 
respectively. Similarly, when the percentage of methanol was increased in methanol: water 
(81:19, v/v) the retention time for DIC and MET were found to be 1.858 and 3.758 minutes, 
respectively. The solution stability study shows that DIC and MET solutions were stable for 
24 h at ambient conditions without any significant degradation of the analyte. The results 
for system suitability parameters were also found to be satisfactory. The obtained results 
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Tab. 3.   Robustness of the method 
  Standard  
condition 
Modified  
conditions 
Retention Time,  
minutes 
Resolution 
DIC  MET 
Mobile phase ratio  80:20 (v/v)  79:21 (v/v) 
81:19 (v/v) 
1.850 
1.858 
3.767 
3.758 
4.79 
4.75 
            Initial time  Final time  % Recovery   
DIC  MET   
Solution stability  0 h  24 h  99.5  100.5   
          System Suitability     
MET  DIC       
Retention time (min)  1.808  3.758       
Theoretical plates  2153  2758       
Asymmetry  1.21  1.13       
Resolution  4.87  –       
 
Limit of detection and Limit of quantitation 
The limit of detection values for DIC  and  MET  were 0.026  µg/ml and 0.03  µg/ml, 
respectively. The limit of quantification values for DIC and MET were 0.088 µg/ml and 
0.1 µg/ml, respectively.  
Analysis of combined tablet dosage form  
The developed method was applied for determination of DIC and MET in their combined 
dosage form. The higher percentage of recovery and non interference of the formulation 
excipients in retention time of the drugs show the selectivity of the method for estimation of 
both drugs in their combined dosage forms.  The result of assay (n=3) for both drugs 
yielded 100.96% (S.D.=±0.91) and 101.09% (S.D.=±0.78) for DIC and MET, respectively, 
from the combined tablet dosage form. 
Conclusion 
A validated stability-indicating RP-HPLC method has been developed for determination of 
DIC and MET in their combined tablet dosage form. The results obtained by the stress 
degradation conditions of the drugs show that the method is specific and stability-
indicating. The drug MET  was  found to be more stable to degradation under different 
stress conditions than compared to DIC. The method was found to be simple, accurate, 
precise and sensitive. The method was successfully applied for the determination of both 
drugs in combined tablet dosage form. In the future,  this method may be applied for 
routine analysis of both the drugs in API, formulations, dissolution studies, bioavailability 
and pharmacokinetic studies.  
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